Filing Flows › Envoy Medical (COCH) › Guidance & outlook

Envoy Medical (COCH) guidance and outlook

Envoy Medical's 10-Q filed Nov 5, 2026 makes 34 forward-looking statements.

Guidance and outlook

34 statements; tone +0.12 (−1 all cautious, +1 all confident); 14 hedged.

Forward-looking statements, 10-Q filed Nov 5, 2026

Upon finalization of the results, we intend to submit a Premarket Approval (“PMA”) application to the FDA.
We expect all Stage 2 participants to complete their 12-month data collection by early Q2 2027, with a PMA submission to the FDA planned to follow a few months thereafter.
As a result, the earliest we currently anticipate obtaining the FDA’s decision on our PMA application is late Q4 of 2027; however, if the FDA pauses the clock or requests a panel review, the FDA’s decision could extend to the first half of 2028.
We plan to submit a total of four modules, with the final module containing final clinical trial data.
By utilizing the modular PMA pathway, we expect to engage with the FDA throughout the review process, allowing for earlier regulatory feedback while establishing a series of defined development milestones.
As a result, we cannot guarantee that we will receive FDA approval on a specific timeline, or at all.
We expect to continue to incur net losses for the foreseeable future, and expect our research and development expenses, sales and marketing expenses, general and administrative expenses, and capital expenditures will continue to increase.
In particular, we expect our expenses to increase as we continue the clinical trial for the Acclaim CI and seek the necessary regulatory approvals for our product candidate.
In addition, if and when we seek and obtain regulatory approval to commercialize the Acclaim CI in the United States, we will also incur increased expenses in connection with commercialization and marketing of such product.
We anticipate that our expenses will increase significantly in connection with our ongoing activities, if and as we:
We expect that our financial performance may fluctuate significantly from quarter-to-quarter and year-to-year due to the development status of our Acclaim CI product and our efforts to obtain regulatory approval and commercialize the Acclaim CI product.
We do not expect to generate any product sales from the Acclaim CI unless and until we successfully complete development and obtain regulatory approval for our product candidate.

Envoy Medical's latest quarter

Envoy Medical, Q3 2026: revenue $66K (+57% year over year), net loss $3.9M, operating cash flow −$5.0M. The chart follows the revenue to costs, profit and cash.

Questions

What does Envoy Medical expect?

Upon finalization of the results, we intend to submit a Premarket Approval (“PMA”) application to the FDA. We expect all Stage 2 participants to complete their 12-month data collection by early Q2 2027, with a PMA submission to the FDA planned to follow a few months thereafter. As a result, the earliest we currently anticipate obtaining the FDA’s decision on our PMA application is late Q4 of 2027; however, if the FDA pauses the clock or requests a panel review, the FDA’s decision could extend to the first half of 2028.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.